https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/659635/akeso-s-ivonescimab-meets-next-phase-iii-lung-cancer-goal-as-competitors-line-uphttps://www.biocentury.com/article/659635/akeso-s-ivonescimab-meets-next-phase-iii-lung-cancer-goal-as-competitors-line-up?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTAKESO’S IVONESCIMAB MEETS NEXT PHASE III LUNG CANCER GOAL, AS COMPETITORS LINE UPIvonescimab leads to overall survival benefit at interim readout of HARMONi-6 presented at ASCO Mon, 01 Jun 2026 18:23:51 -0700https://www.biocentury.com/article/659637/kelonia-data-advance-the-durability-narrative-around-in-vivo-car-ts-at-ascohttps://www.biocentury.com/article/659637/kelonia-data-advance-the-durability-narrative-around-in-vivo-car-ts-at-asco?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTKELONIA DATA ADVANCE THE DURABILITY NARRATIVE AROUND IN VIVO CAR TS AT ASCOPlus: ADC results from Salubris and BeOne, immunocytokine data from Innovent and moreMon, 01 Jun 2026 18:21:41 -0700https://www.biocentury.com/article/659626/the-revolution-will-be-ras-on-in-pancreatic-cancerhttps://www.biocentury.com/article/659626/the-revolution-will-be-ras-on-in-pancreatic-cancer?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTHE REVOLUTION WILL BE RAS(ON) IN PANCREATIC CANCERIn doubling survival in PDAC without major safety signals, RevMed therapy delivers ASCO readout that settles debate over selective RAS(ON) inhibition Mon, 01 Jun 2026 17:23:30 -0700https://www.biocentury.com/article/659628/avenzo-turns-to-rallybio-for-path-to-nasdaq-deals-reporthttps://www.biocentury.com/article/659628/avenzo-turns-to-rallybio-for-path-to-nasdaq-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSAVENZO TURNS TO RALLYBIO FOR PATH TO NASDAQ: DEALS REPORTPlus: Lilly’s pair of Asian deals with Hanmi and Haisco; Edgewise/Servier; and moreMon, 01 Jun 2026 16:45:45 -0700https://www.biocentury.com/article/659629/asco-advances-china-innovation-u-s-science-under-threat-a-biocentury-podcasthttps://www.biocentury.com/article/659629/asco-advances-china-innovation-u-s-science-under-threat-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTASCO ADVANCES, CHINA INNOVATION & U.S. SCIENCE UNDER THREAT — A BIOCENTURY PODCAST Data from RevMed, Akeso in the spotlight in Chicago. Plus: BioCentury’s take on China competition, OMB’s grant proposalMon, 01 Jun 2026 15:56:52 -0700https://www.biocentury.com/article/659617/cmo-roberts-to-succeed-chang-as-allogene-ceohttps://www.biocentury.com/article/659617/cmo-roberts-to-succeed-chang-as-allogene-ceo?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSCMO ROBERTS TO SUCCEED CHANG AS ALLOGENE CEO Plus: FDA veteran Fashoyin-Aje lands at AZ and other biopharma management movesFri, 29 May 2026 17:22:38 -0700https://www.biocentury.com/article/659615/pharma-ceo-silence-is-complicity-in-the-destruction-of-u-s-sciencehttps://www.biocentury.com/article/659615/pharma-ceo-silence-is-complicity-in-the-destruction-of-u-s-science?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYPHARMA CEO SILENCE IS COMPLICITY IN THE DESTRUCTION OF U.S. SCIENCEWhy leaders of the U.S.’s biggest drug companies should use their influence to stop a ruinous proposalFri, 29 May 2026 17:01:44 -0700https://www.biocentury.com/article/659608/busy-june-at-fda-with-11-upcoming-pdufa-dateshttps://www.biocentury.com/article/659608/busy-june-at-fda-with-11-upcoming-pdufa-dates?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEBUSY JUNE AT FDA WITH 11 UPCOMING PDUFA DATESAt least eight new products and three new indications await decisionsFri, 29 May 2026 16:58:32 -0700https://www.biocentury.com/article/659586/cardiovascular-in-licensing-play-kardigan-looking-for-quick-path-to-ipo-finance-reporthttps://www.biocentury.com/article/659586/cardiovascular-in-licensing-play-kardigan-looking-for-quick-path-to-ipo-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCECARDIOVASCULAR IN-LICENSING PLAY KARDIGAN LOOKING FOR QUICK PATH TO IPO: FINANCE REPORTPlus: Editas’ follow-on, Clearnote’s series D and moreFri, 29 May 2026 12:59:34 -0700https://www.biocentury.com/article/659610/covering-12-oncology-programs-pfizer-deal-is-innovent-s-latest-step-toward-global-goalshttps://www.biocentury.com/article/659610/covering-12-oncology-programs-pfizer-deal-is-innovent-s-latest-step-toward-global-goals?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSCOVERING 12 ONCOLOGY PROGRAMS, PFIZER DEAL IS INNOVENT’S LATEST STEP TOWARD GLOBAL GOALSChina-based innovator receives $650M up front, aims to co-commercialize more programs globally in wake of 2025 Takeda dealFri, 29 May 2026 12:51:56 -0700https://www.biocentury.com/article/659598/playing-defense-is-a-losing-strategy-the-u-s-needs-an-offensive-biopharma-planhttps://www.biocentury.com/article/659598/playing-defense-is-a-losing-strategy-the-u-s-needs-an-offensive-biopharma-plan?utm_source=bc_rss&utm_medium=rssBIOCENTURY | GUEST COMMENTARYPLAYING DEFENSE IS A LOSING STRATEGY: THE U.S. NEEDS AN OFFENSIVE BIOPHARMA PLANThe U.S. still leads in biopharma innovation. Defensive policy alone will lose it Thu, 28 May 2026 17:58:00 -0700https://www.biocentury.com/article/659601/three-decades-in-biotech-richard-pops-on-policy-drug-pricing-and-leadershiphttps://www.biocentury.com/article/659601/three-decades-in-biotech-richard-pops-on-policy-drug-pricing-and-leadership?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWTHREE DECADES IN BIOTECH: RICHARD POPS ON POLICY, DRUG PRICING AND LEADERSHIPAlkermes CEO on how policy, economics shape drug development, from the IRA to MFN and beyondThu, 28 May 2026 14:28:02 -0700https://www.biocentury.com/article/659600/take-your-head-out-of-the-sand-on-china-a-perspectivehttps://www.biocentury.com/article/659600/take-your-head-out-of-the-sand-on-china-a-perspective?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYTAKE YOUR HEAD OUT OF THE SAND ON CHINA: A PERSPECTIVEIf half the time spent on hysteria about China went to competing on merits, biotechs and patients would be much better servedThu, 28 May 2026 12:16:20 -0700https://www.biocentury.com/article/659592/post-ipo-kailera-looks-beyond-obesity-to-mashhttps://www.biocentury.com/article/659592/post-ipo-kailera-looks-beyond-obesity-to-mash?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTPOST-IPO, KAILERA LOOKS BEYOND OBESITY TO MASHKAI-4729 adds Kailera and Hengrui to a growing MASH pipeline testing whether glucagon agonism can enhance incretin therapy’s liver benefitWed, 27 May 2026 15:43:24 -0700https://www.biocentury.com/article/659590/science-spotlight-silencing-seizures-by-fixing-gene-mutationshttps://www.biocentury.com/article/659590/science-spotlight-silencing-seizures-by-fixing-gene-mutations?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: SILENCING SEIZURES BY FIXING GENE MUTATIONSBioCentury’s translational roundup also includes a method to restore tertiary lymphoid structures in lung cancer, and papers from six newcosWed, 27 May 2026 15:40:10 -0700https://www.biocentury.com/article/659588/blackstone-backs-apogee-s-atopic-dermatitis-therapy-as-it-heads-to-phase-iiihttps://www.biocentury.com/article/659588/blackstone-backs-apogee-s-atopic-dermatitis-therapy-as-it-heads-to-phase-iii?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSBLACKSTONE BACKS APOGEE’S ATOPIC DERMATITIS THERAPY AS IT HEADS TO PHASE IIIDeal for up to $1.3B accompanies new data showing efficacy signal for long-acting anti-IL-13 moleculeWed, 27 May 2026 15:11:25 -0700https://www.biocentury.com/article/659580/merck-s-post-keytruda-nsclc-play-advances-as-rivals-close-in-at-ascohttps://www.biocentury.com/article/659580/merck-s-post-keytruda-nsclc-play-advances-as-rivals-close-in-at-asco?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMERCK'S POST-KEYTRUDA NSCLC PLAY ADVANCES AS RIVALS CLOSE IN AT ASCOTROP2 ADC and PD-L1 x VEGF bispecific show efficacy in first-line combo studiesTue, 26 May 2026 17:45:38 -0700https://www.biocentury.com/article/659581/asco-preview-china-policy-adc-linkers-a-biocentury-podcasthttps://www.biocentury.com/article/659581/asco-preview-china-policy-adc-linkers-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTASCO PREVIEW, CHINA POLICY, ADC LINKERS — A BIOCENTURY PODCASTPlus: Proposal by Rep. Auchincloss to modernize U.S. clinical trialsTue, 26 May 2026 17:08:46 -0700https://www.biocentury.com/article/659570/ema-s-chmp-backs-four-new-medicines-at-may-meetinghttps://www.biocentury.com/article/659570/ema-s-chmp-backs-four-new-medicines-at-may-meeting?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEEMA'S CHMP BACKS FOUR NEW MEDICINES AT MAY MEETINGOral Wegovy for obesity headlines 11 recommended label extensionsTue, 26 May 2026 17:02:50 -0700https://www.biocentury.com/article/659578/lilly-steps-up-in-vaccines-with-three-acquisitions-deals-reporthttps://www.biocentury.com/article/659578/lilly-steps-up-in-vaccines-with-three-acquisitions-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSLILLY STEPS UP IN VACCINES WITH THREE ACQUISITIONS: DEALS REPORTPharma to obtain Shingrix competitor, clinical S. aureus product, nanoparticle technology and more via trio of takeoutsTue, 26 May 2026 16:26:34 -0700https://www.biocentury.com/article/659573/asco-to-spotlight-pancreatic-cancer-innovation-beyond-krashttps://www.biocentury.com/article/659573/asco-to-spotlight-pancreatic-cancer-innovation-beyond-kras?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTASCO TO SPOTLIGHT PANCREATIC CANCER INNOVATION BEYOND KRASRevolution’s daraxonrasib data will be the marquee event, but abstracts highlight ADCs, bispecifics and diagnostics broadening the field’s approachFri, 22 May 2026 17:15:52 -0700https://www.biocentury.com/article/659571/trump-administration-considering-restrictions-on-china-dealshttps://www.biocentury.com/article/659571/trump-administration-considering-restrictions-on-china-deals?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWTRUMP ADMINISTRATION CONSIDERING RESTRICTIONS ON CHINA DEALSChina hawks are calling for outbound investment bans to be extended to biotechFri, 22 May 2026 16:43:02 -0700https://www.biocentury.com/article/659566/parabilis-follows-up-regeneron-deal-with-ipo-filing-public-equity-reporthttps://www.biocentury.com/article/659566/parabilis-follows-up-regeneron-deal-with-ipo-filing-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEPARABILIS FOLLOWS UP REGENERON DEAL WITH IPO FILING: PUBLIC EQUITY REPORTPlus: Mentari’s reverse merger, offerings by Relay and Immix, and moreFri, 22 May 2026 13:35:56 -0700https://www.biocentury.com/article/659562/europe-s-next-big-growth-fund-could-help-narrow-biotech-s-capital-gaphttps://www.biocentury.com/article/659562/europe-s-next-big-growth-fund-could-help-narrow-biotech-s-capital-gap?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEEUROPE’S NEXT BIG GROWTH FUND COULD HELP NARROW BIOTECH’S CAPITAL GAPEQT’s €5B cross-sector fund could give European biotechs another homegrown option for growth capitalFri, 22 May 2026 12:52:16 -0700https://www.biocentury.com/article/659558/fewer-but-more-concentrated-early-stage-bets-so-far-in-1h26https://www.biocentury.com/article/659558/fewer-but-more-concentrated-early-stage-bets-so-far-in-1h26?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEFEWER BUT MORE CONCENTRATED EARLY-STAGE BETS SO FAR IN 1H26With about a month remaining, seed/series A activity in 1H26 appears down from past halves, but median round size may reach a 10-year highThu, 21 May 2026 14:28:22 -0700https://www.biocentury.com/article/659553/backed-by-westlake-oorja-planning-mid-stage-study-of-ipf-candidate-venture-reporthttps://www.biocentury.com/article/659553/backed-by-westlake-oorja-planning-mid-stage-study-of-ipf-candidate-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEBACKED BY WESTLAKE, OORJA PLANNING MID-STAGE STUDY OF IPF CANDIDATE: VENTURE REPORTPlus: Rounds for cross-border companies Accro and Full-Life, and moreThu, 21 May 2026 12:17:25 -0700https://www.biocentury.com/article/659549/retatrutide-data-strengthen-lilly-s-hand-in-high-bmi-obesityhttps://www.biocentury.com/article/659549/retatrutide-data-strengthen-lilly-s-hand-in-high-bmi-obesity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTRETATRUTIDE DATA STRENGTHEN LILLY’S HAND IN HIGH-BMI OBESITYPhase III data put weight loss above CagriSema’s benchmark, with tolerability that may be good enough to preserve a commercial edgeThu, 21 May 2026 12:09:28 -0700https://www.biocentury.com/article/659538/hengrui-s-deal-economics-pharma-biotech-and-newco-breakdownhttps://www.biocentury.com/article/659538/hengrui-s-deal-economics-pharma-biotech-and-newco-breakdown?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEHENGRUI’S DEAL ECONOMICS: PHARMA, BIOTECH AND NEWCO BREAKDOWNHow Hengrui’s out-licensing deals stack up across partner types, and why last week’s BMS partnership was an outlierWed, 20 May 2026 16:59:02 -0700https://www.biocentury.com/article/659546/auchincloss-developing-clinical-trials-package-to-enhance-u-s-competitivenesshttps://www.biocentury.com/article/659546/auchincloss-developing-clinical-trials-package-to-enhance-u-s-competitiveness?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWAUCHINCLOSS DEVELOPING CLINICAL TRIALS PACKAGE TO ENHANCE U.S. COMPETITIVENESSMassachusetts Democrat seeking feedback on draft proposalWed, 20 May 2026 15:32:43 -0700https://www.biocentury.com/article/659335/poplar-expanding-food-allergy-treatment-with-deeper-ige-depletionhttps://www.biocentury.com/article/659335/poplar-expanding-food-allergy-treatment-with-deeper-ige-depletion?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEPOPLAR: EXPANDING FOOD ALLERGY TREATMENT WITH DEEPER IGE DEPLETIONBy dismantling both IgE signaling and production, start-up aims to create options for patients not reached by XolairWed, 20 May 2026 12:27:47 -0700https://www.biocentury.com/article/659545/as-griffith-retires-dittrich-returns-to-amgen-takes-cfo-rolehttps://www.biocentury.com/article/659545/as-griffith-retires-dittrich-returns-to-amgen-takes-cfo-role?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSAS GRIFFITH RETIRES, DITTRICH RETURNS TO AMGEN, TAKES CFO ROLEPlus: Miralles moves into top R&D position at Artiva; and moreWed, 20 May 2026 12:06:44 -0700https://www.biocentury.com/article/659517/remembering-reiri-visionary-investor-who-championed-japan-s-biotech-sectorhttps://www.biocentury.com/article/659517/remembering-reiri-visionary-investor-who-championed-japan-s-biotech-sector?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSREMEMBERING REIRI: VISIONARY INVESTOR WHO CHAMPIONED JAPAN’S BIOTECH SECTOR Reiri Miura helped build venture firms, companies and networks that strengthened Japan’s biotech industryTue, 19 May 2026 17:31:44 -0700https://www.biocentury.com/article/659535/dueling-memos-are-a-case-study-in-the-politicization-of-scientific-datahttps://www.biocentury.com/article/659535/dueling-memos-are-a-case-study-in-the-politicization-of-scientific-data?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYDUELING MEMOS ARE A CASE STUDY IN THE POLITICIZATION OF SCIENTIFIC DATARelease of underlying data shows how Makary, Prasad, Høeg exaggerated facts to justify gutting vaccine regulationTue, 19 May 2026 16:17:10 -0700https://www.biocentury.com/article/659283/if-ai-becomes-table-stakes-where-is-the-differentiation-a-perspectivehttps://www.biocentury.com/article/659283/if-ai-becomes-table-stakes-where-is-the-differentiation-a-perspective?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYIF AI BECOMES TABLE STAKES, WHERE IS THE DIFFERENTIATION? A PERSPECTIVEShared drug design tools could raise biotech’s baseline capabilities, putting more weight on target selection, validation and iteration speedTue, 19 May 2026 12:56:31 -0700https://www.biocentury.com/article/659515/the-small-but-diverse-lgr5-pipelinehttps://www.biocentury.com/article/659515/the-small-but-diverse-lgr5-pipeline?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTETHE SMALL BUT DIVERSE LGR5 PIPELINEAt least four LGR5-targeted therapies are in development for cancerTue, 19 May 2026 12:43:20 -0700https://www.biocentury.com/article/659510/fda-obesity-targets-and-the-rise-of-dacs-a-biocentury-podcasthttps://www.biocentury.com/article/659510/fda-obesity-targets-and-the-rise-of-dacs-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWFDA, OBESITY TARGETS AND THE RISE OF DACS — A BIOCENTURY PODCASTWhat’s next for FDA as top officials oustedMon, 18 May 2026 16:59:06 -0700https://www.biocentury.com/article/659523/what-s-next-for-fdahttps://www.biocentury.com/article/659523/what-s-next-for-fda?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWWHAT’S NEXT FOR FDADismantling Makary’s FDA was easy, rebuilding will be harderMon, 18 May 2026 16:56:55 -0700https://www.biocentury.com/article/659465/mhra-s-pound-on-aligning-clinical-trial-regulation-with-innovationhttps://www.biocentury.com/article/659465/mhra-s-pound-on-aligning-clinical-trial-regulation-with-innovation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONMHRA’S POUND ON ALIGNING CLINICAL TRIAL REGULATION WITH INNOVATIONJames Pound details MHRA’s strategy for international alignment and regulatory horizon scanningMon, 18 May 2026 15:06:51 -0700https://www.biocentury.com/article/659509/merck-s-trop2-adc-opens-global-women-s-cancer-push-with-endometrial-winhttps://www.biocentury.com/article/659509/merck-s-trop2-adc-opens-global-women-s-cancer-push-with-endometrial-win?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMERCK’S TROP2 ADC OPENS GLOBAL WOMEN’S CANCER PUSH WITH ENDOMETRIAL WINBioCentury’s Clinical Report May 12 – 18Mon, 18 May 2026 15:04:33 -0700https://www.biocentury.com/article/659507/regeneron-buying-stake-in-parabilis-as-part-of-multi-target-helicon-tie-up-deals-reporthttps://www.biocentury.com/article/659507/regeneron-buying-stake-in-parabilis-as-part-of-multi-target-helicon-tie-up-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSREGENERON BUYING STAKE IN PARABILIS AS PART OF MULTI-TARGET HELICON TIE-UP: DEALS REPORTPlus: GSK/Sino hepatitis agreement, Rigel’s PROTAC, a cross-border megadeal and moreMon, 18 May 2026 13:48:42 -0700https://www.biocentury.com/article/659504/pfeifer-retiring-as-ac-immune-ceo-and-more-biotech-c-suite-moveshttps://www.biocentury.com/article/659504/pfeifer-retiring-as-ac-immune-ceo-and-more-biotech-c-suite-moves?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSPFEIFER RETIRING AS AC IMMUNE CEO — AND MORE BIOTECH C-SUITE MOVESNuno Mendonça becomes CMO of Cellular Intelligence; Biocon looks to futureFri, 15 May 2026 16:18:13 -0700https://www.biocentury.com/article/659444/serif-non-viral-dna-delivery-with-goldilocks-durabilityhttps://www.biocentury.com/article/659444/serif-non-viral-dna-delivery-with-goldilocks-durability?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILESERIF: NON-VIRAL DNA DELIVERY WITH ‘GOLDILOCKS’ DURABILITYFlagship’s newest biotech pairs AI-designed DNA with mRNA co-factors for expression that outlasts mRNA without gene therapy's permanenceFri, 15 May 2026 15:59:38 -0700https://www.biocentury.com/article/659463/a-big-year-for-ionishttps://www.biocentury.com/article/659463/a-big-year-for-ionis?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTA BIG YEAR FOR IONISThe RNA therapeutics company is moving from partnering to commercializing products, and from rare to common diseasesFri, 15 May 2026 13:47:31 -0700https://www.biocentury.com/article/659494/cancer-play-impact-doubles-in-value-after-hong-kong-ipo-public-equity-reporthttps://www.biocentury.com/article/659494/cancer-play-impact-doubles-in-value-after-hong-kong-ipo-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCECANCER PLAY IMPACT DOUBLES IN VALUE AFTER HONG KONG IPO: PUBLIC EQUITY REPORTPlus: Delivery company Metis also prices Hong Kong offering; Whitehawk’s PIPEFri, 15 May 2026 12:12:05 -0700https://www.biocentury.com/article/659471/incretins-continue-to-dominate-obesity-conferenceshttps://www.biocentury.com/article/659471/incretins-continue-to-dominate-obesity-conferences?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTINCRETINS CONTINUE TO DOMINATE OBESITY CONFERENCESAn analysis of ECO 2026 abstracts finds just six new targets proposed for obesity; vast majority remain focused on GLP-1RFri, 15 May 2026 11:36:12 -0700https://www.biocentury.com/article/659476/mind-the-gap-parker-institute-s-knudsen-points-to-urgent-need-to-fix-translationhttps://www.biocentury.com/article/659476/mind-the-gap-parker-institute-s-knudsen-points-to-urgent-need-to-fix-translation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONMIND THE GAP: PARKER INSTITUTE’S KNUDSEN POINTS TO URGENT NEED TO FIX TRANSLATIONKnudsen says Parker Institute’s model is replicable, and diagnostics is a good place to startThu, 14 May 2026 18:30:30 -0700https://www.biocentury.com/article/659481/biogen-finds-alzheimer-s-path-for-tau-aso-despite-mixed-datahttps://www.biocentury.com/article/659481/biogen-finds-alzheimer-s-path-for-tau-aso-despite-mixed-data?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTBIOGEN FINDS ALZHEIMER’S PATH FOR TAU ASO DESPITE MIXED DATALow-dose diranersen outperformed higher doses on cognition, giving the company a Phase III path and a dose-response puzzleThu, 14 May 2026 17:44:26 -0700https://www.biocentury.com/article/659229/adc-linkers-get-site-specifichttps://www.biocentury.com/article/659229/adc-linkers-get-site-specific?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTADC LINKERS GET SITE-SPECIFICNew techniques promise more homogeneous ADCs, but added engineering can create yield and manufacturing trade-offsThu, 14 May 2026 16:20:47 -0700https://www.biocentury.com/article/659473/isomorphic-aims-to-scale-new-predictive-ai-model-with-2-1b-venture-reporthttps://www.biocentury.com/article/659473/isomorphic-aims-to-scale-new-predictive-ai-model-with-2-1b-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEISOMORPHIC AIMS TO SCALE NEW PREDICTIVE AI MODEL WITH $2.1B: VENTURE REPORTPlus: Create’s $122M round to back in vivo CAR Ts, and moreThu, 14 May 2026 13:45:49 -0700https://www.biocentury.com/article/659374/3c-therapeutics-making-degrader-antibody-conjugates-plug-and-playhttps://www.biocentury.com/article/659374/3c-therapeutics-making-degrader-antibody-conjugates-plug-and-play?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILE3C THERAPEUTICS: MAKING DEGRADER-ANTIBODY CONJUGATES PLUG AND PLAYAs interest in DACs grows, 3C aims to offer partners a ubiquitous backbone that supports a wide range of targets Wed, 13 May 2026 17:49:23 -0700